enVVeno Medical Corp
$ 11.00
-0.45%
14 Apr - close price
- Market Cap 7,211,700 USD
- Current Price $ 11.00
- High / Low $ 11.20 / 10.73
- Stock P/E N/A
- Book Value 41.36
- EPS -33.06
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -0.56 %
- 52 Week High 196.70
- 52 Week Low 8.67
About
enVVeno Medical Corp is an innovative medical device company dedicated to transforming vascular access solutions for dialysis patients through its proprietary biocompatible technology. By addressing critical unmet needs in the dialysis sector, enVVeno enhances the safety and efficacy of vascular procedures, allowing it to capitalize on the growing vascular interventions market. The company's commitment to advanced engineering, coupled with stringent regulatory compliance, aligns it with the evolving healthcare landscape and reinforces its mission to improve patient outcomes in a vital area of medical care.
Analyst Target Price
$12.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-28 | 2025-07-29 | 2025-05-06 | 2025-02-26 | 2024-10-31 | 2024-07-31 | 2024-05-08 | 2024-02-29 | 2023-10-26 | 2023-07-31 | 2023-04-28 |
| Reported EPS | -5.9092 | -0.23 | -0.33 | -0.22 | -0.3 | -0.35 | -0.31 | -0.31 | -0.36 | -0.45 | -0.58 | -0.57 |
| Estimated EPS | -0.28 | -0.3 | -0.3 | -0.34 | -0.35 | -0.33 | -0.36 | -0.4 | -0.46 | -0.48 | -0.49 | -0.48 |
| Surprise | -5.6292 | 0.07 | -0.03 | 0.12 | 0.05 | -0.02 | 0.05 | 0.09 | 0.1 | 0.03 | -0.09 | -0.09 |
| Surprise Percentage | -2010.4286% | 23.3333% | -10% | 35.2941% | 14.2857% | -6.0606% | 13.8889% | 22.5% | 21.7391% | 6.25% | -18.3673% | -18.75% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVNO
2026-04-07 20:39:17
enVVeno Medical Corporation announced its full-year 2025 financial results, reporting a net loss of $19.5 million and cash balance of $28.2 million. The company is strategically advancing its enVVe® System, a less invasive, transcatheter-based replacement venous valve for severe chronic venous insufficiency. Following successful preclinical studies, enVVeno Medical plans to initiate a pivotal trial for the enVVe System in 2026, aiming to address a significant unmet medical need for 3.5 million patients in the United States.
2026-04-02 00:11:37
enVVeno Medical reported its full-year 2025 financial results, showing a net loss of $19.5 million and a strong cash position of $28.2 million. The company highlighted the strategic advancement of its enVVe® System, a less invasive treatment for severe chronic venous insufficiency, with plans to initiate a pivotal trial in 2026. This system aims to address a significant unmet medical need for millions of patients with no approved surgical or non-surgical replacement venous valves available.
2026-04-01 16:09:49
enVVeno Medical Corporation announced its full-year 2025 financial results, reporting a net loss of $19.5 million and a cash reserve of $28.2 million. The company highlighted its strategic shift towards the less invasive enVVe® System for severe chronic venous insufficiency, with pre-clinical studies completed and preparations for a pivotal trial in 2026 underway. This new system aims to address a significant unmet medical need by providing a non-surgical solution for CVI.
2026-04-01 14:11:37
enVVeno Medical's shares plummeted following the FDA's decision to reaffirm its rejection of the company's investigational device exemption (IDE) application for the VenoValve. The FDA cited manufacturing and design control issues identified during a recent inspection, requesting further data for reconsideration. The company plans to request another meeting with the FDA to discuss next steps, potentially delaying the VenoValve's progress for another six to nine months.
2026-03-31 02:39:54
enVVeno Medical Corporation has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, having maintained the closing bid price above this threshold for 10 consecutive business days. Nasdaq confirmed the matter is closed. The company also reported cash and investments of approximately $28 million as of year-end 2025, which, combined with their compliance, is expected to position them well for their 2026 strategic plans.
2026-03-29 01:10:15
enVVeno Medical reported a fiscal year GAAP EPS of -$33.06, indicating significant financial challenges. The company also announced a reverse stock split to boost its share price and meet exchange listing requirements, but this led to a 20% drop in share price due to negative market sentiment. This situation underscores the need for strategic reevaluation to address ongoing losses and restore investor trust for sustainable growth.
